Naratriptan Viatris (Naratriptan Hydrochloride)

Naratriptan, the active ingredient in Naratriptan Viatris, is a triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults and works by targeting specific serotonin receptors to relieve headache symptoms.\n\nGNH India supplies Naratriptan Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is employed for the acute treatment of migraine, a neurovascular headache disorder mediated by serotonin pathways. It is prescribed for adult patients experiencing moderate to severe migraine attacks.\n\nMigraine (acute): Provides rapid relief of headache pain, nausea, and sensitivity to light and sound during an attack.

Common Side Effects:\n- Tingling or numbness in fingers or toes\n- Flushing or warmth sensation\n- Dizziness or light‑headedness\n- Dry mouth\n- Nausea\n- Fatigue\n\nSerious or Rare Side Effects:\n- Chest pain or tightness (possible cardiac ischemia)\n- Severe hypertension\n- Serotonin syndrome when combined with other serotonergic agents\n- Allergic reactions such as rash, itching, or swelling\n- Persistent visual disturbances\n- Abnormal heart rhythm

Before initiating therapy, consider the following precautions:\n- Cardiovascular disease: assess risk of coronary artery disease or uncontrolled hypertension\n- History of stroke or transient ischemic attack: evaluate cerebrovascular risk\n- Use of other serotonergic drugs: monitor for serotonin syndrome\n- Liver or renal impairment: adjust therapy based on clinical judgment\n- Pregnancy and breastfeeding: discuss potential risks with a healthcare professional\nStore at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Major Interactions (Avoid):\n- Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension\n- Ergot alkaloids: additive vasoconstrictive effects\n- Other triptans or sumatriptan: increased risk of serotonin syndrome\n\nModerate Interactions (Monitor Closely):\n- SSRIs, SNRIs, or other serotonergic antidepressants: monitor for serotonin syndrome\n- CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma levels\n- CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy